Ballicules.com

Griseofulvin

GRIFULVIN

What it isAntifungal disrupting fungal microtubules; dermatophyte infections of hair and skin.

Why this oneMicrosporum tinea capitis is the niche where it can outperform terbinafine.

What limits itLong courses and hepatic enzyme induction complicate use; hormonal contraception and warfarin can lose effect.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Tinea corporis / cruris / capitisAdults375 mg QD (single or divided)375 mg QD
Tinea pedis / unguium (difficult to eradicate)Adults750 mg/day divided750 mg/day divided
Tinea infectionsPediatric (~7.3 mg/kg/day)16-27 kg: 125-187.5 mg QD; >27 kg: 187.5-375 mg QDsame, single daily dose

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Contraindicated — reports of conjoined twins with first-trimester exposure

Lactation Undefined

NO BOXED WARNINGS

Principal riskIt induces CYP3A4, so contraception fails

Cost, est. cash$10–$300/month

Generic entry1982

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityHepatotoxicity and clinically important CYP/QT interactions; organ toxicity varies markedly by agent.

Mechanism of action: Griseofulvin ballicule

Griseofulvin ballicule: receptor binding, kinetics and half-life diagram

Open Griseofulvin in the interactive console ↗

Memory aids: mascots and interaction avatars

Griseofulvin Grifulvin mascot mnemonic cartoon
“Greasy fulcrum”
Griseofulvin CYP3A4 inducer avatar
CYP3A4 inducer (moderate — unverified)

Open Griseofulvin in the interactive console ↗